Pharmacokinetics (PK)
LNA-i-miR-221
Assessment of the PK profile of LNA-i-miR-221 was performed by mass spectrometry analysis of blood and urine samples collected on up to nine occasions up to 12 h post-infusion, using a previously developed analytical method [Serum concentration–time (geometric mean) profiles of LNA-i-mirR-221 by dose 0.5, 1, 2, 3 and 5 mg/kg, on day 1, 2, 3 and 4Across all 4 LNA-i-miR-221 administrations in all cohorts, terminal plasma half-life harmonic mean values ranged from 1.1 to 4.9 h, increasing with the dose. This is unlikely to represent the true terminal half-life of LNA-i-miR-221 and more probably reflects the half-life of an initial distribution/elimination mixed phase. This interpretation is supported by the analysis of LNA-i-miR-221 levels in urine samples, where LNA-i-miR-221, dosed at 0.5 mg/kg, was detectable in the last urine samples collected after the day 4 dose (Additional file 